EnglishРусский中文EspañolDeutsch
Independent world news

FDA approves first drug for neurological symptoms of Gaucher type 3

The US Food and Drug Administration on Wednesday approved Sanofi's oral drug venglustat, sold as Infilbray, as the first treatment for the neurological symptoms of type 3 Gaucher disease, a rare inherited disorder.

FDA approves first drug for neurological symptoms of Gaucher type 3
Photo: Harrison Keely / Wikimedia Commons, CC BY 4.0

The FDA announced the approval on November 18. The agency named Genzyme Corporation, a Sanofi company, as the holder. The label covers adults and children weighing at least 15 kilograms (33 pounds), according to the FDA and trade reports.

The agency said the drug crosses the blood-brain barrier and reduces the build-up of harmful fatty substances in the body and brain. Reuters reported that it works by lowering the production of those substances. Existing therapies such as Cerezyme replace the missing enzyme instead and do not target the neurological effects.

Sanofi had said earlier this year that a clinical study of venglustat met both primary endpoints, with statistically significant improvements in neurological measures compared with standard care. The FDA gave the drug breakthrough therapy status in March and accepted it for priority review in May.

The decision came about a week before the agency's target action date of November 25, according to a secondary report. The reports reviewed did not give a price or a launch date.

Gaucher disease results from a genetic deficiency of an enzyme and can affect the spleen, liver, bones and blood. Type 3 is a form that also involves the nervous system. Infilbray is also under regulatory review for the condition in the European Union and Japan, Reuters reported.

Infilbray FDA approvalvenglustatGaucher disease type 3Sanofi FDA approvalrare neurological disease treatment
More in Science